

**HOLD**

TP: Rs 587 | ▲ 10%

**AMBUJA CEMENTS**

Cement

30 April 2025

## On a strong growth path

- Strong volume-driven revenue growth, as realisation stays soft 3% YoY due to aggressive push in key markets
- Operating cost softened by ~5%/9%YoY/QoQ to Rs 4,003/tn, effectively helps EBITDA margin recovery to 18.3% vs 16.7% YoY.
- We value ACEM's consolidated business at 13x 1YF and revise our TP to Rs 587 (earlier Rs 579). Retain HOLD

**Milind Raginwar**

research@bobcaps.in

**Vol. gains contributed by inorganic growth; realisations listless:** ACEM reported Q4FY25 (standalone) revenue growth of a robust 19%/17% YoY/QoQ to Rs 56.8bn, due to muted realisations on volumes growing a healthy 22%/15% YoY/QoQ to 11.6mn tonnes. Realisation weakened by 3% YoY (+2% QoQ) to Rs 4,806/t. Consolidated revenue grew 11%/6% YoY/QoQ at Rs 98.9bn, as volumes increased 13%/flat YoY/QoQ to 18.7mnt. Blended cement formed 82% of the total trade volumes and premium product share was 29% of trade sales (5.3% YoY).

**EBITDA margin on recovery mode:** Operating cost softened by ~5/9%YoY/QoQ to Rs 4,003/t. Power and fuel costs (adjusted to raw material cost) increased by 4% YoY but fell 7%QoQ to Rs 2,492/t in Q4FY25 from Rs 2,402/t in Q3FY24, due to adverse raw material movement. Kiln Fuel cost reduced by 14% to Rs 1.58 per kcal, given a better fuel mix and higher pet-coke usage. Freight cost fell by 2% to Rs. 1,238/t with the primary lead distance falling by 15 km to 265 km. EBITDA margin recovered to 18.3% from 16.7% YoY. EBITDA/t was at Rs 895 vs Rs840 YoY.

**Capacity expansion on track:** With the acquisition of Penna Cement and Orient Cement, ACEM's cement capacity reached ~104mn tonnes (mnt) (FY25-end). The company is on track to reach 118 mnt by FY26 and 140 mnt by FY28, The Bhatapara clinker unit (4 mnt) and Sankrail/Sindri grinding units are expected to be commissioned by Q1FY26. Nine additional grinding units have been identified to achieve the 140 mnt target by FY28.

**Maintain HOLD:** We maintain EBITDA estimates for FY26/FY27 factoring health volume growth, though realisation growth may be challenging given the heightened competitive pressure in FY26/FY27. Full impact of inorganic growth (ORCMNT + Penna) transition is steady and will continue in near/medium term, pinching cost. We estimate revenue/EBITDA/PAT CAGR of 17%/14%/13% over FY24-FY27. We value ACEM's consolidated business by assigning EV/EBITDA of 13x 1YF earnings and revise our TP to Rs 587 (from Rs 579). Our TP implies a replacement cost of Rs 10bn/mnt – ~33% premium to the industry. We retain HOLD.

## Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	ACEM IN/Rs 534
Market cap	US\$ 12.4bn
Free float	37%
3M ADV	US\$ 17.3mn
52wk high/low	Rs 707/Rs 453
Promoter/FPI/DII	63%/11%/17%


Source: NSE | Price as of 29 Apr 2025

## Key financials

Y/E 31 Mar	FY25P	FY26E	FY27E
Total revenue (Rs mn)	3,50,448	4,58,726	5,25,628
EBITDA (Rs mn)	77,190	76,552	95,901
Adj. net profit (Rs mn)	41,889	34,571	46,997
Adj. EPS (Rs)	18.0	14.0	19.1
Consensus EPS (Rs)	18.0	13.1	17.2
Adj. ROAE (%)	9.0	7.2	8.5
Adj. P/E (x)	29.7	38.0	28.0
EV/EBITDA (x)	13.0	14.9	12.5
Adj. EPS growth (%)	11.7	(21.9)	35.9

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

## Stock performance



Source: NSE



**Fig 1 – Earnings call highlights**

	Q4FY25	Q3FY25	Our view
Volumes and realisations	<p>Ambuja Cements (SA) volume in Q4FY25, was up 22% YoY. Growth was driven by a strong micro-market strategy, expansion of the ground network, and a high proportion of blended cement (82%) and premium products (29.1% of trade sales, up 5.3% YoY). Cement demand grew by 6.5-7% in Q4FY25. For the full FY25, industry growth was 4-5%, with Ambuja outperforming the industry.</p> <p>Share of premium cement increased to 29%, with a target of 35% by FY26.</p>	<p>Demand is expected to grow by 4-5% in FY25, further supported by the pro-infra and housing Budget 2025. As per management, ACEM will continue to grow at a faster pace than the industry.</p> <p>Blended cement formed 82% of total trade volumes, and premium product share as a percentage of trade sales was 26% (vs 22% YoY).</p>	<p>Contributions from Sanghi Industries (SIL) and the Penna Cement acquisition should help ACEM stay ahead of industry growth in FY26/FY27. Orient Cement and a clear capacity addition roadmap only confirms ACEM's firm volume growth in the medium term.</p>
Margins & cost reduction	<p>Continuous cost reduction initiatives undertaken by ACEM are visible.</p> <p>The operational cost for Q4FY25 was Rs 4,003/t.</p> <p>Kiln Fuel cost reduced by 14% to Rs 1.58 per kcal, due to a better fuel mix and increased use of pet-coke.</p> <p>Transportation costs also fell by 2% to Rs. 1,238/t. The primary lead distance was reduced by 15 km to 265 km, and the secondary lead distance by 2 km to 46 km. Direct dispatch to customers increased by 600 bps to 58%.</p> <p>ACEM achieved cost savings of Rs 150-175/t so far, with a cost target of Rs 3,650/t by FY28 (an additional Rs 300-325/t to be achieved by FY28).</p>	<p>Continuous decline in realisation impact on cost reduction initiatives undertaken by ACEM due to transition is visible.</p> <p>Power and fuel costs slid by 7% to Rs 1,260/t in Q3FY25 from Rs 1,353/t in Q3FY24. Freight cost declined by 6% to Rs 1,239/t YoY. The overall lead reduced by 4km (from 289km to 285km).</p> <p>Kiln fuel cost reduced by 10% to Rs 1.66/kcal from 1.84/kcal due to increased use of low cost imported pet-coke.</p> <p>Management has indicated a cost reduction target of Rs 530/t to Rs 3,650/t by FY28 with progressive Rs 100-150/t in cost savings every year.</p>	<p>For ACEM logistics cost rationalisation, prudent rail-road mix and warehouse optimisation will be the key as it improves further on the grinding units and its presence across additional regions. Energy cost benefits may be limited only to green energy usage due to the base effect. However, the transitionary phase is clearly hitting the core performance and will be watched keenly.</p>
Capacity	<p>Ambuja Cements has crossed 100 mnt of cement capacity. This includes the acquisition of Orient Cement, commissioning of the Farakka grinding unit, and debottlenecking of various plants.</p> <p>Sanghi's utilisation is at 40-45%, Penna's at 75-80% for clinker and 45-50% for cement, and Orient's at 60-75%.</p> <p>The company is on track to reach 118 mnt by FY26 and 140 mnt by FY28, with nine grinding units across regions.</p> <p>The Bhatapara clinker unit (4 mnt) and Sankrail/Sindri grinding units are expected to be commissioned by Q1FY26.</p> <p>Nine additional grinding units have been identified to achieve the 140 mnt target by FY28.</p>	<p>With the Sindri, Farakka and Sankrail grinding units in advanced stages of completion, acquisition of Orient Cements (OCL) transaction, operational capacities to reach 104mt by Q4FY25, 118mt by FY26 and 140mt target by FY28.</p> <p>Bhatapara Line 3 of clinker capacity is expected to be commissioned in Q4FY25 to supply the above GU.</p> <p>By Mar'25 ACEM expects Sanghi and Penna to reach a capacity utilisation of 80-85% from the current low levels of 40-50%.</p>	<p>Thus far, ACEM's growth has been driven by inorganic growth. Organic growth will testify to the company's execution capacity. Capacity expansion is on firm track and new capacities are likely to affirm growth even beyond FY27.</p>

	Q4FY25	Q3FY25	Our view
Green energy	<p>WHRs capacity is at 218 mw, the company is targeting 30% of power needs by FY28.</p> <p>300 mw of RE capacity in place (200 MW solar and ~100 MW wind) and is targeting 1,000 MW by FY26.</p> <p>Green power share increased to 26% (from 15.6%), reducing power costs by Rs 0.20-0.25 per unit.</p> <p>ACEM managed to secure a 10-year supply of 5 bnt at a negative cost of Rs 400/t with Adani Power</p>	<p>Waste Heat Recovery System (WHRs) is currently at 197MW and targeted to reach 218MW by Q4FY25 as per management.</p> <p>The commissioned 200MW of solar power at Khavda will lower power costs in upcoming quarters, as a part of ACEM's ongoing investments in 1,000MW of renewable energy (RE). Green power share increased to 21.5% from 15.8% YoY</p>	<p>ACEM's initiatives to shift to alternative energy sources, have picked up pace. However, thermal power remains key for core clinker/cement production.</p>
Capex	<p>Growth capex is planned to be Rs 60 bn; Efficiency capex Rs 25-30 bn for FY26, totalling approximately Rs 90 bn.</p> <p>Cash deployment in FY25 was to the tune of Rs 56bn for acquiring a 46% stake in Orient Cement, Rs 20bn for the open offer escrow.</p> <p>Cash and equivalents were at ~Rs 100 bn as of March 2025, approximately Rs 50 bn post-Orient acquisition.</p>	<p>ACEM spent Rs 62bn on capex in 9MFY25 and expects to end FY25 with a capex of Rs 90bn.</p>	<p>Capex guidance in line with the capacity growth ACEM has targeted.</p>
Other relevant information	<p>Acquired 367 mnt of limestone reserves in Q4FY25, bringing the total to over 9,000 mnt.</p> <p>Ordered 11 GPWIS rakes (all delivered) and 26 BCFC rakes (8 delivered) for clinker and fly ash transport.</p> <p>Initiatives like the Query-to-Lorry system and Cement Network Operating Centre (CNOC) are enhancing efficiency.</p> <p>Provisioned around Rs 2 bn for non-operational assets (Bargarh, Chaibasa and Wadi).</p> <p>Net worth increased to Rs 640 bn (up from Rs 500 bn YoY); the company remains debt-free with the highest credit rating in the industry.</p>	<p>Cash and cash equivalent was Rs 87.55bn by Q3FY25.</p> <p>631mt of limestone reserves were acquired in Q3FY25 taking total reserves to 8.3bnt [Besides this, high quality limestone reserves of OCL adds to existing resources.</p> <p>Eight new RMC plants commissioned in Q3FY25, taking the total to 100.</p> <p>Merger of Penna and Sanghi Cement with Adani Cement is awaiting regulatory approvals and going forward management intends to reduce the number of entities.</p>	<p>Securing limestone reserves only adds comfort over the expansion drive staying seamless.</p> <p>ACEM's balance sheet is healthy despite strong capex plans as of now.</p>

Source: Company, BOBCAPS Research

**Fig 2 – Key quarterly metrics**

	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	Q4FY25E	Deviation (%)
Volumes (mn mt)	11.6	9.5	22.1	10.1	14.9	10.61	9.38
Cement realisations (Rs/t)	4,898	5,032	(2.7)	4,806	1.9	5026	(2.54)
Operating costs (Rs/t)*	4,003	4,192	(4.5)	4,399	(9.0)	4229	(5.34)
EBITDA/t (Rs)	895	840	6.6	407	119.9	797	12.30


Source: Company, BOBCAPS Research

**Fig 3 – Key quarterly metrics**

(Rs mn)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	Q4FY25E	Deviation (%)
<b>Net Sales</b>	<b>56,814</b>	<b>47,803</b>	<b>18.8</b>	<b>48,537</b>	<b>17.1</b>	<b>53,297</b>	<b>6.6</b>
<b>Expenditure</b>							
Change in stock	811	879	(7.8)	1,233		64	
Raw material	7,149	4,075	75.5	7,552	(5.3)	7,891	(9.4)
Purchased products	11,501	8,988	28.0	9,532	20.7	10,043	14.5
Power & fuel	9,448	8,878	6.4	8,662	9.1	8,961	5.4
Freight	10,795	10,465	3.1	9,643	11.9	10,022	7.7
Employee costs	1,451	1,319	9.9	1,425	1.8	1,455	(0.3)
Other exp	5,278	5,221	1.1	6,377	(17.2)	6,409	(17.7)
<b>Total Operating Expenses</b>	<b>46,432</b>	<b>39,825</b>	<b>16.6</b>	<b>44,426</b>	<b>4.5</b>	<b>44,844</b>	<b>3.5</b>
<b>EBITDA</b>	<b>10,382</b>	<b>7,978</b>	<b>30.1</b>	<b>4,111</b>	<b>152.5</b>	<b>8,452</b>	<b>22.8</b>
EBITDA margin (%)	18.3	16.7	159bps	8.5	980bps	15.9	242bps
Other Income	4,421	1,768	150.0	2,546	73.6	2,210	100.0
Interest	(131)	338	(138.7)	355	(136.9)	375	(134.9)
Depreciation	2,964	2,440	21.5	2,529	17.2	2,650	11.8
PBT	11,970	6,968	71.8	3,774	217.2	7,637	56.7
Non-recurring items	0	(158)	0.0	7,066	0.0	0	NM
PBT (after non-recurring items)	11,970	7,126	68.0	(3,293)	(463.5)	7,637	56.7
Tax	2,681	1,487	80.3	1,508	77.8	1,833	0.0
<b>Reported PAT</b>	<b>9,289</b>	<b>5,323</b>	<b>74.5</b>	<b>17,580</b>	<b>(47.2)</b>	<b>5,804</b>	<b>60.0</b>
Adjusted PAT	9,289	5,481	69.5	2,266	310.0	5,804	60.0
NPM (%)	16.3	11.5	488bps	4.7	1168bps	10.9	546bps
<b>Adjusted EPS (Rs)</b>	<b>4.7</b>	<b>2.8</b>	<b>69.5</b>	<b>1.1</b>	<b>310.0</b>	<b>2.9</b>	<b>60.0</b>


Source: Company, BOBCAPS Research

**Fig 4 – Volume growth driven by aggressive push across regions with focus on East**




Source: Company, BOBCAPS Research

**Fig 5 – Pricing pressure reverses from the Q3 lows**




Source: Company, BOBCAPS Research

**Fig 6 – EBITDA/t still stays far below YoY but reverses QoQ**




Source: Company, BOBCAPS Research

**Fig 7 – Operating cost savings measures are commendable**




Source: Company, BOBCAPS Research

**Fig 8 – Freight cost likely to contribute savings in mid-term**



Source: Company, BOBCAPS Research

**Fig 9 – Green energy may further boost fuel cost savings**



Source: Company, BOBCAPS Research

## Valuation methodology

We maintain our EBITDA estimates for FY26/FY27 factoring health volume growth, though realisation growth may be challenging given the heightened competitive pressure in FY26/FY27. Full impact of inorganic growth (ORCMNT + Penna) transition is steady and will continue in the near/medium term pinching cost.

Current phase of transition of the newly-acquired assets, pressure in overcrowded markets on prices and excessive volume push may have some impact on the performance in the interim period. We will keenly watch this and accordingly remain vigilant to the changing business environment and performance of ACEM.

We estimate revenue/EBITDA/PAT CAGR of 17%/14%/13% over FY24-FY27. We value ACEM's consolidated business by assigning EV/EBITDA of 13x 1YF earnings and revise our TP to Rs 587 (from Rs 579).

Our TP implies a replacement cost of Rs 10bn/mnt – ~33% premium to the industry. We retain HOLD

**Fig 10 – Valuation summary**

Business (Rs mn)	FY27E
Target EV/EBITDA (x)	13
EBITDA	95,901
Target EV	11,99,724
Total EV	11,99,724
Net debt	(2,46,269)
Target market capitalisation	14,46,093
<b>Target price (Rs/sh)</b>	<b>587</b>
Weighted average shares (mn)	2197.7


Source: BOBCAPS Research| Valuations are 1-year forward Dec-2026

**Fig 11 – Peer comparison**

Ticker	Rating	TP (Rs)	EV/EBITDA (x)			EV/tonne (US\$)			ROE (%)			ROCE (%)		
			FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E
ACEM IN	HOLD	587	13.0	14.9	12.5	193	183	175	9.0	7.2	8.5	10.2	9.3	11.1
ACC IN	HOLD	2,154	15.4	9.3	7.8	110.6	101.2	90.9	8.2	11.5	13.3	9.7	13.9	15.7
UTCEM IN	BUY	13,919	25.3	17.6	14.4	304.24	278.26	246.81	10.0	14.4	16.8	12.9	17.8	21.1
SRCM IN	HOLD	25,755	24.8	23.5	19.4	140.6	140.0	121.6	4.9	8.0	10.6	6.7	10.5	13.4


Source: BOBCAPS Research

**Fig 12 – EV/EBITDA band: Current valuations reflect earnings trajectory**




Source: Company, Bloomberg, BOBCAPS Research

**Fig 13 – EV/EBITDA 1YF: Valuations reflect concerns over competitive intensity impacting earnings**




Source: Company, Bloomberg, BOBCAPS Research

**Fig 14 – EV/tonne: Replacement cost at fair valuations**



Source: Company, Bloomberg, BOBCAPS Research

**Fig 15 – EV/tonne 1YF: Valuations ahead can moderate**



Source: Company, Bloomberg, BOBCAPS Research

## Key risks

Key risks to our estimates:

- Increased competitive pressure in the next two years can pose downside risks to our estimates.
- Faster-than-expected demand revival can raise growth ahead of our estimates, representing an upside risk.
- Rising fuel costs due to geo-political issues can pose downside risk to earnings.



## Financials

### Income Statement

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25P	FY26E	FY27E
<b>Total revenue</b>	<b>3,84,449</b>	<b>3,25,442</b>	<b>3,50,448</b>	<b>4,58,726</b>	<b>5,25,628</b>
EBITDA	51,224	63,995	77,190	76,552	95,901
Depreciation	(16,447)	(16,234)	(24,783)	(21,608)	(23,634)
EBIT	42,154	59,425	61,466	64,516	81,890
Net interest inc./(exp.)	(1,949)	(2,764)	(2,159)	(2,990)	(3,308)
Other inc./(exp.)	7,377	11,664	9,059	9,572	9,623
Exceptional items	0	0	0	0	0
EBT	40,205	56,662	59,306	61,526	78,582
Income taxes	(7,051)	(11,626)	(7,640)	(14,307)	(18,059)
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	(4,130)	(11,383)	(9,778)	(12,648)	(13,526)
<b>Reported net profit</b>	<b>29,024</b>	<b>33,652</b>	<b>41,889</b>	<b>34,571</b>	<b>46,997</b>
Adjustments	0	0	0	0	0
<b>Adjusted net profit</b>	<b>29,024</b>	<b>33,652</b>	<b>41,889</b>	<b>34,571</b>	<b>46,997</b>

### Balance Sheet

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25P	FY26E	FY27E
Accounts payables	72,283	63,338	69,671	76,638	84,302
Other current liabilities	42,707	55,711	66,569	59,104	60,877
Provisions	2,795	2,989	3,139	3,296	3,461
Debt funds	4,860	7,414	8,416	7,917	7,950
Other liabilities	7,004	15,491	24,076	24,557	25,048
Equity capital	3,971	3,971	4,395	4,926	4,926
Reserves & surplus	3,13,010	4,10,155	5,29,506	5,58,905	6,00,471
Shareholders' fund	3,87,565	5,08,035	6,37,583	6,80,385	7,35,702
<b>Total liab. and equities</b>	<b>5,17,214</b>	<b>6,52,978</b>	<b>8,09,454</b>	<b>8,51,898</b>	<b>9,17,340</b>
Cash and cash eq.	29,610	1,10,689	61,722	2,40,663	2,54,319
Accounts receivables	11,544	12,131	15,903	12,568	14,401
Inventories	32,728	36,086	42,480	30,163	34,562
Other current assets	1,80,423	1,35,118	1,45,600	1,46,170	1,51,337
Investments	2,137	8,486	18,511	1,087	1,196
Net fixed assets	1,42,485	1,92,413	2,19,137	2,55,018	2,90,046
CWIP	1,13,922	1,22,211	2,70,278	1,30,428	1,35,699
Intangible assets	4,366	35,846	35,823	35,802	35,780
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
<b>Total assets</b>	<b>5,17,215</b>	<b>6,52,978</b>	<b>8,09,454</b>	<b>8,51,898</b>	<b>9,17,340</b>

### Cash Flows

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25P	FY26E	FY27E
<b>Cash flow from operations</b>	<b>10,675</b>	<b>1,13,362</b>	<b>81,775</b>	<b>84,002</b>	<b>82,851</b>
Capital expenditures	(31,773)	(1,03,923)	(1,99,553)	82,384	(63,912)
Change in investments	(155)	(6,349)	(10,026)	17,424	(109)
Other investing cash flows	0	0	0	0	0
<b>Cash flow from investing</b>	<b>(31,928)</b>	<b>(1,10,272)</b>	<b>(2,09,578)</b>	<b>99,807</b>	<b>(64,021)</b>
Equities issued/Others	(4,996)	1,00,331	420	755	225
Debt raised/repaid	431	2,554	1,002	(499)	33
Interest expenses	0	0	0	0	0
Dividends paid	(13,027)	(4,964)	(4,973)	(5,125)	(5,431)
Other financing cash flows	(48,487)	(19,933)	82,388	0	0
<b>Cash flow from financing</b>	<b>(66,079)</b>	<b>77,988</b>	<b>78,836</b>	<b>(4,868)</b>	<b>(5,174)</b>
<b>Chg in cash &amp; cash eq.</b>	<b>(87,333)</b>	<b>81,078</b>	<b>(48,967)</b>	<b>1,78,941</b>	<b>13,656</b>
<b>Closing cash &amp; cash eq.</b>	<b>29,610</b>	<b>1,10,689</b>	<b>61,721</b>	<b>2,40,663</b>	<b>2,54,319</b>

### Per Share

Y/E 31 Mar (Rs)	FY23A	FY24A	FY25P	FY26E	FY27E
Reported EPS	11.7	16.1	18.0	14.0	19.1
Adjusted EPS	11.7	16.1	18.0	14.0	19.1
Dividend per share	5.0	2.4	2.1	2.1	2.2
Book value per share	195.2	242.9	273.6	276.2	298.7

### Valuations Ratios

Y/E 31 Mar (x)	FY23A	FY24A	FY25P	FY26E	FY27E
EV/Sales	2.7	2.9	2.9	2.5	2.3
EV/EBITDA	20.2	15.0	13.0	14.9	12.5
Adjusted P/E	45.7	33.2	29.7	38.0	28.0
P/BV	2.7	2.2	2.0	1.9	1.8

### DuPont Analysis

Y/E 31 Mar (%)	FY23A	FY24A	FY25P	FY26E	FY27E
Tax burden (Net profit/PBT)	82.5	79.5	87.1	76.7	77.0
Interest burden (PBT/EBIT)	95.4	95.3	96.5	95.4	96.0
EBIT margin (EBIT/Revenue)	11.0	18.3	17.5	14.1	15.6
Asset turnover (Rev./Avg TA)	79.3	55.6	47.9	55.2	59.4
Leverage (Avg TA/Avg Equity)	1.4	1.3	1.3	1.3	1.2
Adjusted ROAE	9.3	10.1	9.0	7.2	8.5

### Ratio Analysis

Y/E 31 Mar	FY23A	FY24A	FY25P	FY26E	FY27E
<b>YoY growth (%)</b>					
Revenue	7.6	5.8	7.7	30.9	14.6
EBITDA	(34.0)	56.2	20.6	(0.8)	25.3
Adjusted EPS	(20.0)	37.6	11.7	(21.9)	35.9
<b>Profitability &amp; Return ratios (%)</b>					
EBITDA margin	13.1	19.3	21.0	16.4	18.0
EBIT margin	10.8	17.9	16.7	13.9	15.4
Adjusted profit margin	7.5	10.3	12.0	7.5	8.9
Adjusted ROAE	9.3	10.1	9.0	7.2	8.5
ROCE	9.2	12.8	10.2	9.3	11.1

### Working capital days (days)

Receivables	14	14	17	10	10
Inventory	39	40	44	24	24
Payables	97	86	88	72	70

### Ratios (x)

Gross asset turnover	1.6	1.0	0.9	1.0	1.1
Current ratio	2.2	2.4	1.9	3.1	3.1
Net interest coverage ratio	21.6	21.5	28.5	21.6	24.8
Adjusted debt/equity	0.0	0.0	0.0	0.0	0.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

**Recommendation scale: Recommendations and Absolute returns (%) over 12 months**

**BUY** – Expected return >+15%


**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

## Ratings and Target Price (3-year history): AMBUJA CEMENTS (ACEM IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

## Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

## General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### **Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014**

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### **Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### **Distribution into the United Kingdom (“UK”):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### **No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

#### **Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.